低维纳米材料在阿尔茨海默病中的应用:当前的应用
Yijing Shi1, Wen Luo1, Yazhou Hu1
1School of Physical Science and Technology, Ningbo University, Ningbo 315211, China.
Current Alzheimer research
|October 27, 2025
概括
低维纳米材料 (LDNMs) 为阿尔茨海默氏症提供了一个有前途的多目标疗法.
科学领域:
- 纳米技术和材料科学 材料科学
- 神经科学和药理学 神经科学和药理学
- 生物医学工程 生物医学工程
背景情况:
- 阿尔茨海默病 (AD) 是一种复杂的神经退行性疾病,其特点是粉样β聚合,高酸化,氧化应激和神经炎症.
- 目前的AD疗法面临挑战,包括血脑屏障 (BBB) 穿透能力差以及对纳米级病理聚合物的有效性有限.
- 低维纳米材料 (LDNMs) 正在成为潜在的多目标治疗药物.
研究的目的:
- 审查LDNM作为阿尔茨海默病多目标治疗平台的潜力.
- 建立一种理解LDNM与AD核心病理相互作用的范式.
- 为设计基于LDNM的AD纳米疗法提供框架.
主要方法:
- 对零维 (0D),一维 (1D) 和二维 (2D) 的纳米结构进行系统评估.
- 为LDNM-AD病理相互作用建立一个"纳米-纳米"相互作用范式.
- 实验数据总结量化LDNM对AD特征和药物输送的影响.
主要成果:
- LDNM有效地抑制了β-粉样蛋白 (Aβ) 聚合和高酸化.
- LDNMs可以减轻氧化应激,恢复金属离子恒温,并减少神经炎症.
- LDNM显示出跨越血脑屏障 (BBB) 的向药物输送潜力.
结论:
- LDNM的多目标功能克服了单个目标AD疗法的局限性.
- LDNM纳米尺寸和可修改的表面促进了与AD病理的协同相互作用.
- LDNM提供了一个整体的干预策略和开发新型AD纳米疗法的框架.
关键词:
阿尔茨海默病 阿尔茨海默病一个Aβ聚合的Aβ聚合.血液-大脑屏障是什么?低维纳米材料是一种低维纳米材料.药物输送系统是药物输送系统.纳米载体. 纳米载体.纳米医药是一种纳米医药.氧化应激是一种氧化应激.蛋白质是一种蛋白质.更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.5K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.4K
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
552
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
552